Exonate
Exonate develops and licenses Vascular Endothelial Growth Factors (VEGF) control agents that may be used as therapeutics in areas such as pain control, macular degeneration and cancer.
Drug discovery – wet AMD and cancer
School of Medicine
Profile
Exonate’s research in this area has identified therapeutic candidates for wet Age Related Macular Degeneration that can be administered as a simple eye drop, thereby over-coming the unpleasant need for monthly injections in the eye.
Competing injectable anti-VEGFdirected therapy currently constitutes the gold-standard treatment for wet Age Related Macular Degeneration (wAMD) and other neovascular diseases of the eye.
News and press releases
University spin-out named as a Bloomberg UK start-up to watch
- 25th October 2023 10:38 am·
Researchers develop new platform that could replace the use of animals in research
- 3rd August 2023 11:20 am·
Spin-out company launched to deliver gene therapy during bone repair surgery
- 13th June 2023 11:48 am·
Lewis Capaldi visits the Neupulse office to try out our wearable wrist device
- 30th January 2023 3:04 pm·
Neupulse raises £918k in a second round of funding
- 20th January 2023 1:05 pm·
Alevin wins Best Biotech Startup Company award at the prestigious OBN Awards 2022
- 19th November 2022 2:34 pm·
SurePulse and partners land £1.4m Innovate UK award
- 2nd November 2022 1:37 pm·
PBD Biotech raises further £2.4m for its breakthrough tuberculosis blood test
- 27th October 2022 11:40 am·
Nottingham trio share award for brain imaging innovation
- 27th October 2022 11:28 am·
Face and voice recognition technology set to transform diagnosis of perinatal depression
- 20th October 2022 4:01 pm·
BlueSkeye AI wins ‘One to Watch’ Award at Medilink Business Awards 2022
- 2nd February 2022 12:22 pm·
Data privacy startup ID Ward raises €1.1 million to launch its decentralised advertising technology
- 2nd February 2022 11:53 am·